HER2-enriched breast cancers are negative for ER and PR but overexpress HER2 whereas basal-like (BL) breast cancers do not express ER, PR or HER2 and are often used synonymously with triple-negative breast cancer (TNBC). This evidence concerns the gene PGR and breast carcinoma.